Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Perphenazine”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 163 records · Page 9Linked to original sources
PubMed2005

Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss.

In this pilot study, we have investigated the effects of switching from olanzapine or risperidone treatment to low-dose perphenazine combined with buspirone in six schizophrenic patients who had experienced weight gain. We found no relapse as to psychotic symptoms measured by the CGI-S scale and no exacerbation of extrapyramidal side-effects as measured by the Simpson-Angus Scale. In addition, we observed a medium weight reduction of 10.5 kg (range 1-20 kg).

Adult↗
PubMed1981

Amitriptyline and perphenazine (Triptafen DA) in chronic pain.

One-hundred and twenty patients with chronic pain, who had all failed to obtain relief with traditional medical treatment, were given a standard psychotropic drug mixture consisting of amitriptyline 25 mg and perphenazine 2 mg. Of those who completed 2 months of treatment, 33.68% were pain free, while 8.3% had unacceptable side-effects. The best results were obtained in patients with postherpetic neuralgia and postoperative scar pain.

Amitriptyline↗
PubMed1976

Clinical pharmacokinetic studies of perphenazine.

A gas-chromatographic method was used for the study in man of the kinetics of perphenazine (PPZ) and its sulphoxide metabolite (PPZ-SO). Various forms of PPZ administration were applied in eighteen schizophrenic patients and four healthy volunteers. Following an i.v. dose of 5 or 6 mg a considerable fluctuation in the plasma concentration was noted before the exponential elimination phase. The average terminal half-life of PPZ was approximately 9.5 hours. PPZ-SO showed up quickly but in low concentrations. After an oral dose of 6 mg no PPZ was detected in plasma and PPZ-SO only as traces. During continuous oral medication, 12 mg three times daily, a low systemic availability and a high PPZ-SO/PPZ ratio was found suggesting a marked first pass effect. PPZ-enanthate given i.m. fortnightly resulted in PPZ-levels comparable to those seen after continuous oral medication, but PPZ-SO concentration were much lower. No accumulation was observed. The systemic clearance rate (average approximately 100 1/h) was the same after PPZ-enanthate i.m. and PPZ i.v., but varied three-fold individually. Side effects were mostly, but not always, registered concomitant with high plasma levels of PPZ.

Administration, Oral↗
PubMed1979

Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergic drugs.

1. A gas chromatographic method was applied to study plasma levels of perphenazine (PPZ) and its major metabolites in man before and during simultaneous antiparkinson treatment. Twenty-six psychotic patients received various forms of PPZ administration as well as antiparkinson drugs. 2. Biperidine (5 mg) was administered intravenously to each of five patients, who 5 days earlier had had a single dose of PPZ-enanthate i.m. No significant alterations in plasma concentrations of PPZ were observed. 3. In fourteen patients receiving oral PPZ treatment the plasma levels of PPZ and its metabolites did not deviate significantly from controls after addition of biperidine or orphenadine given for 3 weeks in fixed oral doses. 4. The ratio between PPZ plasma concentration measured 4 and 7 h after the morning dose was not affected by concomitant antiparkinson therapy. 5. It is concluded that no clinically relevant pharmacokinetic interaction takes place between PPZ and two generally used antiparkinson drugs during steady-state conditions in psychotic patients.

Administration, Oral↗
PubMed1980

Abscesses following prolonged intramuscular administration of perphenazine enantate.

In an investigation of 109 patients on neuroleptics in a vegetable oil base, four of the patients developed abscesses at the site of deposits of perphenazine enantate given intramuscularly in large doses every 1-4 weeks. Observations suggested that the risk of such a complication could be minimized by limiting the frequency of administration to once a fortnight, by limiting the dose injected, by frequent variation of the site of injection, and by regular use of a disinfectant.

Abscess↗
PubMed1993

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations.

Risperidone (RIS), a new neuroleptic with 5-HT2- and dopamine D2 receptor-blocking properties, was compared with perphenazine (PER) in a double-blind, multicentre, parallel-group study in 107 chronic schizophrenics with acute exacerbation. RIS 5-15 mg or PER 16-48 mg daily was given for 8 weeks. Psychopathology was assessed with the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression. Seventy-eight patients completed the trial; there was an equal number of dropouts on both drugs. The mean daily dose at endpoint was 8.5 mg RIS and 28 mg PER. The reduction in total PANSS score to endpoint did not differ significantly, although there was a tendency in favour of RIS. The number of patients with predominantly negative symptoms who showed at least 20% reduction in total PANSS score was significantly larger in the RIS group. Furthermore, the number of patients showing at least 20% reduction in Brief Psychiatric Rating Scale (BPRS) score (BPRS being a subscale of PANSS) was significantly larger in the RIS group. The hostility cluster of BPRS improved more on RIS than on PER in the endpoint analysis. The overall prevalence of side effects was fairly similar in the two groups.

Acute Disease↗
PubMed1980

Effect of perphenazine on secretory patterns of growth hormone in the rat.

A nonstressfull frequent sampling technique was employed to determine the effect of perphenazine, 5 mg/kg on spontaneous secretion of rat growth hormone (rGH). The drug blocked secretion almost entirely for at least 3, but no more than 22 h. These results suggest a role for dopamine and/or norepinephrine as stimulatory neurotransmitters for spontaneous rGH secretory episodes. The further suggest that experimental or therapeutic use of phenothiazines might produce functional GH deficiency.

Animals↗
PubMed1982

Interaction between antidepressants and perphenazine in psychiatric inpatients.

In a study of 99 patients receiving amitriptyline or nortriptyline alone and 60 patients receiving one of these antidepressants in combination with perphenazine, the patients receiving the combination medication had up to 70% higher antidepressant plasma levels than patients receiving the antidepressant alone. The groups did not differ significantly in sex, age, smoking behavior, or antidepressant dose level. Due to the possibility of side effects from such combination medication, the authors recommend that depressed patients not responding to the tertiary amine tricyclic antidepressants receive a trial of high doses of the drugs before antidepressant-neuroleptic combinations are administered.

Adult↗
PubMed1991

Effects of bromocriptine and perphenazine on prolactin and progesterone concentrations in pregnant pony mares during late gestation.

Pregnant pony mares in Group A (n = 4) received i.m. injections at 07:00 and 17:00 h of 0.8 mg bromocriptine/kg body weight 0.75 per day beginning on Day 295 of gestation and continuing until parturition. Group B (n = 4) was treated similarly, but perphenazine was administered orally at 0.375 mg/kg body weight twice a day beginning on Day 305 of gestation and continuing until parturition. Mares in Group C (n = 3) received i.m. injections of saline. Mean plasma prolactin and progesterone concentrations were greater (P less than 0.05) for mares in Group C than in Groups A and B from 295 to 309 days of gestation. From 305 days of gestation, plasma prolactin and progesterone concentrations were greater (P less than 0.05) in Group B and C than in Group A mares. Progesterone and prolactin concentrations increased over this period for Group B and Group C mares, but remained constant in Group A mares. From 10 days pre partum through foaling, mares in Group A had lower progesterone (P less than 0.05) and prolactin (P less than 0.01) concentrations than Group B and C mares. All mares in Group A were agalactic at foaling, while all mares in Groups B and C had normal milk secretion. Gestation was longer (P less than 0.05) in Group A than in Group C mares. In Group A, 2 mares retained the placenta for greater than 3 h, 3 mares had dystocia and all 4 mares had thickened, haemorrhagic placentae.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1992

Difference between effects of chlorpromazine and perphenazine on microsomal phospholipids and enzyme activities in rat liver.

The effects of acute administration of chlorpromazine (CPZ) and perphenazine (PPZ) on hepatic microsomal phospholipids (PLs) and enzyme activities in the male rat were examined in order to elucidate the relationship between individual PLs and drug-metabolizing activity. Cytochrome P-450 and aniline (AN) hydroxylation activity were initially decreased in CPZ-treated rats, but cytochrome P-450 subsequently recovered to a level not significantly different from the control and AN hydroxylation was markedly increased, while in PPZ-treated rats, they remained depressed. CPZ increased the activities of glycerophosphate acyltransferase (GPA) and choline phosphotransferase (CPT), while PPZ increased the activities of phosphatidate cytidylyltransferase (PCT), phosphatidate phosphohydrolase (PPH) and CPT. Concurrently, CPZ raised microsomal phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine-inositol (PSI) and sphingomyelin (SM), while PPZ increased PC and PE, but did not affect the levels of PSI and SM. Acyl components of phospholipids were also modified. CPZ significantly decreased the ratio of saturated to unsaturated fatty acids, particularly in the PC and PE fractions, while the effect of PPZ was only slight. The results imply that an increase of AN hydroxylation activity may involve the incorporation of unsaturated fatty acids into enzyme-associated PC and PE.

Aniline Hydroxylase↗
PubMed1981

Effects of bromocriptine and perphenazine on male accessory sex glands. I. The seminal vesicles.

The effects of bromocriptine and perphenazine on C3H/HeJ mouse seminal vesicles were studied. The response of the stroma and parenchyma of the glands to the hormones differed. Testosterone repressed stromal proliferation. Prolactin had no observable stromal effect but influenced the response of the parenchyma. In castrated mice, low levels of prolactin were associated with abnormal epithelial mitotic activity and atypical cytology while elevated prolactin levels resulted in a nonatrophic epithelium similar to that from the seminal vesicles of intact individuals. In the absence of testicular testosterone, prolactin may exert an inhibitory influence on glandular proliferation.

Animals↗
PubMed1999

Acquired aplastic anemia secondary to perphenazine.

Aplastic anemia, defined by the presence of pancytopenia and hypocellular bone marrow in the absence of any abnormal blood cells, is a serious complication of antipsychotic drug treatment. While hematological side effects from antipsychotic medications are rare, recent experience with clozapine, an atypical antipsychotic agent, has raised the awareness of clinicians to the serious and potentially fatal hematological changes that can occur with antipsychotic medications. A case of perphenazine-induced aplastic anemia in a 23-year-old schizophrenic man is reported.

Adult↗
PubMed1975

[Clinical study on five depot neuroleptics. Comparison of effective profiles of fluphenazinedecanoate, fluspirilene, penfluridol, perphenazine-enanthate and pipothiazinepalmitate].

Five depot neuroleptics (fluphenazinedeconoate, fluspirilene, pipothiazinepalmitate, penfluridol and perphenazine-enanthate) were compared based on clinical trials in subacute and chronic schizophrenic patients. The psychopathological symptoms were documented by means of the AMP-system. Statistical analyses showed several differences between the effects of the five substances. The AMP-system proved a useful instrument to differentiate similar drugs.

Administration, Oral↗
PubMedDate not supplied

The rat brain as a "deep compartment" in the kinetics of a common metabolite of prochlorperazine and perphenazine.

N-[gamma-(2-Chlorophenothiazin-10-yl)propyl]ethylenediamine (Cl-PPED), a common metabolite of prochlorperazine and perphenazine, was orally administered to male rats at a dose of 50 mg/kg, and its concentrations in plasma, liver, lung, kidney, and brain were followed from 6 hr to 40 days after dosage. Small quantities were measured by two-dimensional thin-layer chromatography of a fluorescent derivative and in situ fluorometry of the chromatograms. The kinetic behavior of Cl-PPED in brain differed from that in other tissues in that the concentration maximum was achieved later and the elimination half-life was distinctly longer (8 days vs. 1.2-3 days). Cl-PPED was evenly among the three major brain regions. Subcellular fractionation of liver and brain revealed preferential localization in mitochondria.

Animals↗
PubMedDate not supplied

Simultaneous determination of promethazine, chlorpromazine, and perphenazine by multivariate calibration methods and derivative spectrophotometry.

Partial least-squares (PLS) regression, singular value decomposition-based PLS, and an artificial neural network (ANN) were tested as calibration procedures for the simultaneous determination of promethazine, chlorpromazine, and perphenazine by both conventional and derivative spectrophotometry. Comparison of the results revealed that the application of the ANN to the derivative spectra is superior to the application of the 2 PLS methods used. Different binary and ternary synthetic mixtures of the phenothiazine drugs in pure form and in tablets were analyzed by the proposed method, and acceptable results were obtained.

Calibration↗